Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.

被引：2
|
作者：
Rahbar, Kambiz
Ahmadzadehfar, Hojjat
Kratochwil, Clemens
Baum, Richard P.
Schmidt, Matthias
Pfestroff, Andreas
Prasad, Vikas
Heinzel, Aelxander
Ruf, Juri
Eveslage, Maria
Boegemann, Martin
Fendler, Wolfgang
Krause, Bernd J.
机构：
[1] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
[2] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
[3] Heidelberg Univ, Dept Nucl Med, Heidelberg, Germany
[4] Zentralklin Bad Berka, Bad Berka, Germany
[5] Univ Cologne, Dept Nucl Med, Cologne, Germany
[6] Univ Marburg, Dept Nucl Med, Marburg, Germany
[7] Charite, Dept Nucl Med, Med Ctr, Berlin, Germany
[8] Univ Aachen, Dept Nucl Med, Aachen, Germany
[9] Univ Freiburg, Dept Nucl Med, Freiburg, Germany
[10] Univ Hosp Muenster, IBKF, Munster, Germany
[11] Univ Munster, Med Ctr, Munster, Germany
[12] Univ Munich LMU, Dept Nucl Med, Munich, Germany
[13] Univ Rostock, Dept Nucl Med, Rostock, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.155
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
155
引用
收藏
页数：1
相关论文
共 50 条
  • [1] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [2] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [3] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [4] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [5] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
  • [6] Radioligand Therapy with 177Lu-PSMA-617 in Patients with Diffuse Bone Marrow Involvement: Safety and Efficacy
    Groner, Daniel
    Ngoc, Christina Nguyen
    Davis, Karen
    Happel, Christian
    Baumgarten, Justus
    Banek, Severine
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [7] German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Haberkorn, Uwe
    Schaefers, Michael
    Essler, Markus
    Baum, Richard P.
    Kulkarni, Harshad R.
    Schmidt, Matthias
    Drzezga, Alexander
    Bartenstein, Peter
    Pfestroff, Andreas
    Luster, Markus
    Luetzen, Ulf
    Marx, Marlies
    Prasad, Vikas
    Brenner, Winfried
    Heinzel, Alexander
    Mottaghy, Felix M.
    Ruf, Juri
    Meyer, Philipp Tobias
    Heuschkel, Martin
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang Peter
    Krause, Bernd Joachim
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (01) : 85 - 90
  • [8] German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Haberkorn, Uwe
    Schaefers, Michael
    Essler, Markus
    Baum, Richard P.
    Kulkarni, Harshad R.
    Schmidt, Matthias
    Drzezga, Alexander
    Bartenstein, Peter
    Pfestroff, Andreas
    Luster, Markus
    Luetzen, Ulf
    Marx, Marlies
    Prasad, Vikas
    Brenner, Winfried
    Heinzel, Alexander
    Mottaghy, Felix M.
    Ruf, Juri
    Meyer, Philipp Tobias
    Heuschkel, Martin
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang Peter
    Krause, Bernd Joachim
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 : 257S - 262S
  • [9] 177Lu-PSMA-617 vs Cabazitaxel in MCRPC
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 13N - 13N
  • [10] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
12345